Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q3 2019 · 10-Q
Revenue$186.30M$186.30M−7.9% vs Q3 2018 Net Income-$20.60M-$20.60MN/M vs Q3 2018 EPS Diluted-$0.28-$0.28N/M vs Q3 2018 Operating Income-$20,900,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Free Cash Flowderived$14,400,000+121.5% Margins · derivedOperating margin-11.2%−11.8 pt vs Q3 2018
Net margin-11.1%−10.7 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 6, 2019 · 37 d after period end